Ignite Creation Date:
2025-12-24 @ 9:22 PM
Ignite Modification Date:
2025-12-25 @ 7:09 PM
Study NCT ID:
NCT04745832
Status:
TERMINATED
Last Update Posted:
2024-11-04
First Post:
2021-02-04
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Sponsor:
MEI Pharma, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-13
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-20
Completion Date Type:
ACTUAL
First Submit Date:
2021-02-04
First Submit QC Date:
None
Study First Post Date:
2021-02-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-10-02
Results First Submit QC Date:
None
Results First Post Date:
2023-12-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-31
Last Update Post Date:
2024-11-04
Last Update Post Date Type:
ACTUAL